Back to Journals » Cancer Management and Research » Volume 9

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

Authors El-Amm J, Nassabein R, Aragon-Ching JB

Received 10 April 2017

Accepted for publication 30 May 2017

Published 11 July 2017 Volume 2017:9 Pages 299—306

DOI https://doi.org/10.2147/CMAR.S139305

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Antonella D'Anneo


Joelle El-Amm,1 Rami Nassabein,1 Jeanny B Aragon-Ching2

1Division of Hematology and Oncology, Department of Internal Medicine, Lebanese American University, Beirut, Lebanon; 2GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA


Abstract: Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. There has been a lot of interest and emphasis in the evaluation of patient-related outcomes (PROs) as it relates to quality of life, pain, adverse events, fatigue, and among others, in the use of different agents that have been shown to improve survival. This review examines the companion PROs in conjunction with abiraterone acetate use. This is ­particularly relevant since PROs are increasingly viewed as a key metric for drug label claims in granting approval across regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency.

Keywords: abiraterone acetate, metastatic castration-resistant prostate cancer, patient-related outcomes, androgen signaling agents

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]